Pfizer Management record

PFEPfizer Inc.SEC filings, as filedCross-checked

The record

• Share count change (weighted average basic shares), FY2009 to FY2025−18.9%Share count change (weighted average basic shares), FY2009 to FY2025SEC EDGAR · CIK 00000780030001193125-10-042425 · FY2009 · period ended 2009-12-31 · filed 2010-02-26WeightedAverageNumberOfSharesOutstandingBasic0000078003-26-000026 · FY2025 · period ended 2025-12-31 · filed 2026-02-26WeightedAverageNumberOfSharesOutstandingBasicFY2009: 7,007,000,000Weighted average basic shares, FY2009SEC EDGAR · CIK 00000780030001193125-10-042425 · FY2009 · period ended 2009-12-31 · filed 2010-02-26WeightedAverageNumberOfSharesOutstandingBasicFY2025: 5,683,000,000Weighted average basic shares, FY2025SEC EDGAR · CIK 00000780030000078003-26-000026 · FY2025 · period ended 2025-12-31 · filed 2026-02-26WeightedAverageNumberOfSharesOutstandingBasic
• Stock-based compensation as a share of free cash flow, FY20258.8%Stock-based compensation as a share of free cash flow, FY2025SEC EDGAR · CIK 00000780030000078003-26-000026 · FY2025 · period ended 2025-12-31 · filed 2026-02-26NetCashProvidedByUsedInOperatingActivities0000078003-26-000026 · FY2025 · period ended 2025-12-31 · filed 2026-02-26PaymentsToAcquirePropertyPlantAndEquipment0000078003-26-000026 · FY2025 · period ended 2025-12-31 · filed 2026-02-26ShareBasedCompensation
• Net income minus dividends, FY2016–FY2025$51.2 billion^rNet income minus dividends, FY2016–FY2025SEC EDGAR · CIK 00000780030000078003-17-000014 · FY2016 · period ended 2016-12-31 · filed 2017-02-23NetIncomeLoss0000078003-17-000014 · FY2016 · period ended 2016-12-31 · filed 2017-02-23PaymentsOfOrdinaryDividends0000078003-18-000027 · FY2017 · period ended 2017-12-31 · filed 2018-02-22NetIncomeLoss0000078003-18-000027 · FY2017 · period ended 2017-12-31 · filed 2018-02-22PaymentsOfOrdinaryDividends0000078003-19-000015 · FY2018 · period ended 2018-12-31 · filed 2019-02-28NetIncomeLoss0000078003-19-000015 · FY2018 · period ended 2018-12-31 · filed 2019-02-28PaymentsOfOrdinaryDividends0000078003-20-000014 · FY2019 · period ended 2019-12-31 · filed 2020-02-27NetIncomeLoss0000078003-20-000014 · FY2019 · period ended 2019-12-31 · filed 2020-02-27PaymentsOfOrdinaryDividends0000078003-21-000038 · FY2020 · period ended 2020-12-31 · filed 2021-02-25NetIncomeLoss0000078003-21-000038 · FY2020 · period ended 2020-12-31 · filed 2021-02-25PaymentsOfOrdinaryDividends0000078003-22-000027 · FY2021 · period ended 2021-12-31 · filed 2022-02-24NetIncomeLoss0000078003-22-000027 · FY2021 · period ended 2021-12-31 · filed 2022-02-24PaymentsOfOrdinaryDividends0000078003-23-000024 · FY2022 · period ended 2022-12-31 · filed 2023-02-23NetIncomeLoss0000078003-23-000024 · FY2022 · period ended 2022-12-31 · filed 2023-02-23PaymentsOfOrdinaryDividends0000078003-24-000039 · FY2023 · period ended 2023-12-31 · filed 2024-02-22NetIncomeLoss0000078003-24-000039 · FY2023 · period ended 2023-12-31 · filed 2024-02-22PaymentsOfOrdinaryDividends0000078003-25-000054 · FY2024 · period ended 2024-12-31 · filed 2025-02-27NetIncomeLoss0000078003-25-000054 · FY2024 · period ended 2024-12-31 · filed 2025-02-27PaymentsOfOrdinaryDividends0000078003-26-000026 · FY2025 · period ended 2025-12-31 · filed 2026-02-26NetIncomeLoss0000078003-26-000026 · FY2025 · period ended 2025-12-31 · filed 2026-02-26PaymentsOfOrdinaryDividendsr: a later 10-K shows a different figure for NetIncomeLoss FY2019; NetIncomeLoss FY2020. As filed is shown.Change in public float (non-affiliate market value at the end of each year's second quarter, as reported in the 10-K): −$78.0 billionChange in public floatSEC EDGAR · CIK 00000780030000078003-17-000014 · FY2016 · period ended 2016-07-03 · filed 2017-02-23dei:EntityPublicFloat0000078003-26-000026 · FY2025 · period ended 2025-06-29 · filed 2026-02-26dei:EntityPublicFloatRounded in the filing: dei:EntityPublicFloat FY2016; dei:EntityPublicFloat FY2025.

Lines without a figure for Pfizer

The reason is given with each line; the methodology explains which inputs each line needs.

• Average price paid per repurchased shareMissingAverage price paid per repurchased shareFY2025: buyback amount missing — no figure in the XBRL data for 2025-01-01 to 2025-12-31 (searched: PaymentsForRepurchaseOfCommonStock, PaymentsForRepurchaseOfEquity; USD)FY2025: buyback amount missing — no figure in the XBRL data for 2025-01-01 to 2025-12-31 (searched: PaymentsForRepurchaseOfCommonStock, PaymentsForRepurchaseOfEquity; USD)
• Price-to-earnings paid on buybacksMissingPrice-to-earnings paid on buybacksFY2025: buyback amount missing — no figure in the XBRL data for 2025-01-01 to 2025-12-31 (searched: PaymentsForRepurchaseOfCommonStock, PaymentsForRepurchaseOfEquity; USD)FY2025: buyback amount missing — no figure in the XBRL data for 2025-01-01 to 2025-12-31 (searched: PaymentsForRepurchaseOfCommonStock, PaymentsForRepurchaseOfEquity; USD)
• Net debt divided by operating incomeMissingNet debt divided by operating incomeno fiscal year has all the inputsNo fiscal year has all the inputs
• Operating income divided by interest expenseMissingOperating income divided by interest expenseno fiscal year has all the inputsNo fiscal year has all the inputs
• Gross margin, fiscal 2021–22 against fiscal 2018–20MissingGross margin, fiscal 2021–22 against fiscal 2018–20gross margin missing in one of the years 2018–2022Gross margin missing in one of the years 2018–2022
• Change in shares outstandingMissingChange in shares outstandingFY2025: shares outstanding missing — no figure in the XBRL data at 2025-12-31 (searched: CommonStockSharesOutstanding; shares)FY2025: shares outstanding missing — no figure in the XBRL data at 2025-12-31 (searched: CommonStockSharesOutstanding; shares)